AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.
UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.
IMPORTANT SAFETY INFORMATION
Contraindication: Concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).
The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).
Please see full Prescribing Information at https://media.allergan.com/products/Ubrelvy_pi.pdf.
Copyright © 2021 Maine Neurological Society - All Rights Reserved.